REGENERON PHARMACEUTICALS, INC. Lease Obligation Incurred
REGENERON PHARMACEUTICALS, INC. (REGN) reported Lease Obligation Incurred of $0 for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-07.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:CapitalLeaseObligationsIncurred · last filed 2020-02-07
- REGENERON PHARMACEUTICALS, INC. lease obligation incurred for the quarter ending 2018-03-31 was $0.00, a 100.00% decline year-over-year.
- REGENERON PHARMACEUTICALS, INC. lease obligation incurred for the quarter ending 2017-12-31 was $0.00, a 100.00% decline year-over-year.
- REGENERON PHARMACEUTICALS, INC. lease obligation incurred for the quarter ending 2017-09-30 was $0.00.
- REGENERON PHARMACEUTICALS, INC. lease obligation incurred for the quarter ending 2017-06-30 was $0.00.
- REGENERON PHARMACEUTICALS, INC. lease obligation incurred for fiscal 2019 was $0.00.
- REGENERON PHARMACEUTICALS, INC. lease obligation incurred for fiscal 2018 was $0.00, a 100.00% decline from fiscal 2017.
- REGENERON PHARMACEUTICALS, INC. lease obligation incurred for fiscal 2017 was $201.20M, a 29.89% increase from fiscal 2016.
- REGENERON PHARMACEUTICALS, INC. lease obligation incurred for fiscal 2016 was $154.90M.
| Period end | Lease Obligation Incurred 3 month | Lease Obligation Incurred 6 month | Lease Obligation Incurred 9 month | Lease Obligation Incurred 12 month | Lease Obligation Incurred 12 month as first filed |
|---|---|---|---|---|---|
| 2019-12-31 | $0.00 10-K · filed 2020-02-07 | ||||
| 2018-12-31 | $0.00 10-K · filed 2020-02-07 | ||||
| 2018-03-31 | $0.00 10-Q · filed 2018-05-03 | $0.00 derived: sum of 2 quarters · filed 2020-02-07 | $0.00 derived: sum of 3 quarters · filed 2020-02-07 | $0.00 derived: sum of 4 quarters · filed 2020-02-07 | |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-07 | $0.00 derived: sum of 2 quarters · filed 2020-02-07 | $0.00 derived: sum of 3 quarters · filed 2020-02-07 | $201.20M 10-K · filed 2020-02-07 | |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $0.00 derived: sum of 2 quarters · filed 2018-11-06 | $201.20M 10-Q · filed 2018-11-06 | $356.10M derived: sum of 4 quarters · filed 2019-02-07 | |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | $201.20M 10-Q · filed 2018-08-02 | $356.10M derived: sum of 3 quarters · filed 2019-02-07 | $356.10M derived: sum of 4 quarters · filed 2019-02-07 | |
| 2017-03-31 | $201.20M 10-Q · filed 2018-05-03 | $356.10M derived: sum of 2 quarters · filed 2019-02-07 | $356.10M derived: sum of 3 quarters · filed 2019-02-07 | $356.10M derived: sum of 4 quarters · filed 2019-02-07 | |
| 2016-12-31 | $154.90M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-07 | $154.90M derived: sum of 2 quarters · filed 2019-02-07 | $154.90M derived: sum of 3 quarters · filed 2019-02-07 | $154.90M 10-K · filed 2019-02-07 | $0.00 10-K · filed 2017-02-09 |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $0.00 derived: sum of 2 quarters · filed 2017-11-08 | $0.00 10-Q · filed 2017-11-08 | ||
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $0.00 10-Q · filed 2017-08-03 | |||
| 2016-03-31 | $0.00 10-Q · filed 2017-05-04 | ||||
| 2012-12-31 | $0.00 10-K · filed 2013-02-15 | ||||
| 2011-12-31 | $700.00K 10-K · filed 2013-02-15 | ||||
| 2010-12-31 | $2.90M 10-K · filed 2013-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |